Immunovant, Inc. Files 10-Q for Period Ending December 31, 2023

TL;DR

<b>Immunovant, Inc. filed its Q3 2024 10-Q, detailing financial data and corporate information.</b>

AI Summary

Immunovant, Inc. (IMVT) filed a Quarterly Report (10-Q) with the SEC on February 12, 2024. Immunovant, Inc. reported its Q3 2024 financial results. The company's fiscal year ends on March 31. The filing covers the period from October 1, 2023, to December 31, 2023. Key financial data points such as preferred stock, common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings are detailed for various periods. The company's principal executive offices are located at 320 West 37th Street, New York, NY 10018.

Why It Matters

For investors and stakeholders tracking Immunovant, Inc., this filing contains several important signals. This 10-Q filing provides a detailed look at Immunovant's financial position and performance for the third quarter of fiscal year 2024, which is crucial for investors to assess the company's health and operational progress. The specific financial data points and historical comparisons within the filing are essential for understanding Immunovant's capital structure, equity changes, and overall financial trajectory.

Risk Assessment

Risk Level: low — Immunovant, Inc. shows low risk based on this filing. The filing is a standard 10-Q report, providing routine financial disclosures without immediate indicators of significant new risks or positive developments.

Analyst Insight

Review the detailed financial statements and equity breakdowns to understand Immunovant's capital structure and recent financial performance.

Key Numbers

• 2023-12-31 — Reporting Period End Date (CONFORMED PERIOD OF REPORT)
• 2024-02-12 — Filing Date (FILED AS OF DATE)
• 03-31 — Fiscal Year End (FISCAL YEAR END)
• 2836 — Standard Industrial Classification (STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Key Players & Entities

• Immunovant, Inc. (company) — FILER
• Health Sciences Acquisitions Corp (company) — FORMER COMPANY
• New York (location) — CITY
• DE (location) — STATE OF INCORPORATION

Forward-Looking Statements

• Immunovant will continue to increase its common stock value in the next fiscal year. (Immunovant, Inc.) — medium confidence, target: 2025-03-31

FAQ

Industry Context

Immunovant operates in the biotechnology sector, focusing on the development of therapies. This sector is characterized by high research and development costs and significant regulatory oversight.

Regulatory Implications

As a biotechnology company, Immunovant is subject to stringent regulations from bodies like the FDA regarding drug development, clinical trials, and market approval.

What Investors Should Do

1. Analyze the detailed balance sheet and statement of stockholders' equity for changes in capital accounts.
2. Note the specific dates and periods covered by the financial data to ensure accurate trend analysis.
3. Verify the company's principal business address and incorporation state for corporate record-keeping.

Key Dates

• 2023-12-31: Quarterly Period End — Covers the financial results for the third quarter of fiscal year 2024.
• 2024-02-12: Filing Date — Date the 10-Q report was officially filed with the SEC.

Year-Over-Year Comparison

This filing represents the standard quarterly report (10-Q) for Immunovant, Inc., providing updated financial information compared to previous filings.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Sto

Filing Documents

• imvt-20231231.htm (10-Q) — 1299KB
• exhibit101-20231231q3.htm (EX-10.1) — 60KB
• exhibit311-20231231q3.htm (EX-31.1) — 9KB
• exhibit312-20231231q3.htm (EX-31.2) — 9KB
• exhibit321-20231231q3.htm (EX-32.1) — 4KB
• exhibit322-20231231q3.htm (EX-32.2) — 4KB
• 0001764013-24-000026.txt (&nbsp;) — 5024KB
• imvt-20231231.xsd (EX-101.SCH) — 27KB
• imvt-20231231_cal.xml (EX-101.CAL) — 38KB
• imvt-20231231_def.xml (EX-101.DEF) — 192KB
• imvt-20231231_lab.xml (EX-101.LAB) — 491KB
• imvt-20231231_pre.xml (EX-101.PRE) — 321KB
• imvt-20231231_htm.xml (XML) — 402KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets as of December 31, 2023 and March 31, 2023 4 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended December 31 2023 and 2022 5 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended December 31, 2023 and 2022 6 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended December 31, 2023 and 2022 7 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2023 and 2022 8 Notes to Condensed Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 31

Controls and Procedures

Item 4. Controls and Procedures 31

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 32

Risk Factors

Item 1A. Risk Factors 32

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 86

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 86

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 86

Other Information

Item 5. Other Information 86

Exhibits

Item 6. Exhibits 87

SIGNATURES

SIGNATURES 88 Where You Can Find More Information Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (www.immunovant.com), filings we make with the Securities and Exchange Commission, webcasts, press releases, and conference calls. We use these mediums, including our website, to communicate with our stockholders and the public about our company, our product candidate, and other matters. It is possible that the information that we make available may be deemed to be material information. We therefore encourage investors and others interested in our company to review the information that we make available on our website. The information contained on the website referenced in this Quarterly Report on Form 10-Q is not incorporated by reference into this filing, and the website address is provided only as an inactive textual reference. All trademarks, trade names, service marks, and copyrights appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. 1 Table of Contents SUMMARY RISK FACTORS You should consider carefully the risks described under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q. References to "we," "us," and "our" in this section titled "Summary Risk Factors" refer to Immunovant, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: Our business is currently dependent on the successful and timely development, regulatory approval and commercialization of our product candidates, batoclimab and IMVT-1402. Our product candidates, or anti-FcRn product candidates developed by others, may cause adverse events or undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontin

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements IMMUNOVANT, INC. Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share and per share data) December 31, 2023 March 31, 2023 Assets Current assets: Cash and cash equivalents $ 690,937 $ 376,532 Accounts receivable 1,029 700 Prepaid expenses and other current assets 18,810 27,101 Total current assets 710,776 404,333 Operating lease right-of-use assets 294 1,172 Property and equipment, net 376 333 Total assets $ 711,446 $ 405,838 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,910 $ 1,353 Accrued expenses 27,886 40,771 Current portion of operating lease liabilities 306 1,173 Total current liabilities 32,102 43,297 Operating lease liabilities, net of current portion — 47 Total liabilities 32,102 43,344 Commitments and contingencies (Note 9) Stockholders' equity: Series A preferred stock, par value $ 0.0001 per share, 10,000 shares authorized, issued and outstanding at December 31, 2023 and March 31, 2023 — — Preferred stock, par value $ 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and March 31, 2023 — — Common stock, par value $ 0.0001 per share, 500,000,000 shares authorized, 145,094,052 shares issued and outstanding at December 31, 2023 and 500,000,000 shares authorized, 130,329,863 shares issued and outstanding at March 31, 2023 14 13 Additional paid-in capital 1,430,294 927,976 Accumulated other comprehensive (loss) income ( 600 ) 852 Accumulated deficit ( 750,364 ) ( 566,347 ) Total stockholders' equity 679,344 362,494 Total liabilities and stockholders' equity $ 711,446 $ 405,838 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents IMMUNOVANT, INC. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) Three Months Ended December 31, Nine Months Ended

View Full Filing

View this 10-Q filing on SEC EDGAR